Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05975554 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Study acronym: ELLIPSE
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Aug 1, 2025 to Feb 1, 2025
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trail is to compare the differences in carotid plaque Treg cells' gene signature for activation, proliferation, and suppressive function using scRNA-seq in patients treated with IL-2 compared to control.
Trial Details
NCT Number NCT05975554
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Conditions
(from sponsor)		 TIA, Carotid Artery Plaque, Carotid Atherosclerosis
Related terms Carotid Artery Diseases, Carotid Stenosis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov